Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W.

Drugs. 2010 Mar 26;70(5):513-28. doi: 10.2165/11533070-000000000-00000. Review.

PMID:
20329802
2.

Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.

Wang T, Xie XX, Ji M, Wang SW, Zha J, Zhou WW, Yu XL, Wei C, Ma S, Xi ZY, Pang GL, Liu RT.

Neuropharmacology. 2016 Jun;105:561-76. doi: 10.1016/j.neuropharm.2016.02.015. Epub 2016 Feb 18.

PMID:
26907803
3.

Naturally occurring autoantibodies against β-Amyloid.

Bach JP, Dodel R.

Adv Exp Med Biol. 2012;750:91-9. doi: 10.1007/978-1-4614-3461-0_7. Review.

PMID:
22903668
4.

Clinical trials of intravenous immunoglobulin for Alzheimer's disease.

Relkin N.

J Clin Immunol. 2014 Jul;34 Suppl 1:S74-9. doi: 10.1007/s10875-014-0041-4. Epub 2014 Apr 24. Review.

PMID:
24760112
5.

Intravenous immunoglobulins for Alzheimer's disease.

Puli L, Tanila H, Relkin N.

Curr Alzheimer Res. 2014;11(7):626-36. Review.

PMID:
25115546
6.

Intravenous immunoglobulin and Alzheimer's disease immunotherapy.

Solomon B.

Curr Opin Mol Ther. 2007 Feb;9(1):79-85. Review.

PMID:
17330405
7.

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M.

J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90.

8.

Amyloid-beta immunotherapy for Alzheimer's disease.

Fu HJ, Liu B, Frost JL, Lemere CA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. Review.

9.

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.

Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA.

Curr Pharm Des. 2011;17(5):508-20. Review.

PMID:
21375481
10.

Immunomodulation and AD--down but not out.

Knight EM, Gandy S.

J Clin Immunol. 2014 Jul;34 Suppl 1:S70-3. doi: 10.1007/s10875-014-0039-y. Epub 2014 Apr 30. Review.

PMID:
24781637
11.

Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

Counts SE, Lahiri DK.

Curr Alzheimer Res. 2014;11(7):623-5. No abstract available.

PMID:
25156573
12.

A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.

Schenk DB, Seubert P, Grundman M, Black R.

Neurodegener Dis. 2005;2(5):255-60. Review.

PMID:
16909006
13.

[Immunotherapy for Alzheimer's disease targeting Aβ].

Tabira T.

Nihon Rinsho. 2016 Mar;74(3):423-6. Japanese.

PMID:
27025080
14.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80. Review.

PMID:
21091109
15.

Antibody-based therapy in Alzheimer's disease.

Pul R, Dodel R, Stangel M.

Expert Opin Biol Ther. 2011 Mar;11(3):343-57. doi: 10.1517/14712598.2011.552884. Epub 2011 Jan 25. Review.

PMID:
21261567
16.

Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?

Li Y, Liu Y, Wang Z, Jiang Y.

Expert Opin Biol Ther. 2013 Nov;13(11):1515-22. doi: 10.1517/14712598.2013.838555. Epub 2013 Sep 22. Review.

PMID:
24053611
17.

Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Boche D, Denham N, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Sep;120(3):369-84. doi: 10.1007/s00401-010-0719-5. Epub 2010 Jul 15. Review.

PMID:
20632020
18.

Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.

Klaver AC, Coffey MP, Smith LM, Loeffler DA.

Immunol Lett. 2013 Jul-Aug;154(1-2):7-11. doi: 10.1016/j.imlet.2013.07.008. Epub 2013 Aug 6.

PMID:
23928186
19.

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M.

J Neurosci. 2011 Apr 13;31(15):5847-54. doi: 10.1523/JNEUROSCI.4401-10.2011.

20.

Alternative Abeta immunotherapy approaches for Alzheimer's disease.

Town T.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. Review.

Supplemental Content

Support Center